Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.67B 3.21B 2.96B 2.73B 5.14B 353B 5.25B 35.36B 13.91B 173B 13.78B 13.47B 596B P/E 2026 *
-50.3x
P/E 2027 * -99.2x
Enterprise Value 3.53B 3.09B 2.85B 2.63B 4.95B 340B 5.06B 34.06B 13.4B 167B 13.27B 12.98B 574B EV / Sales 2026 *
12.3x
EV / Sales 2027 * 9.92x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day+3.71%
1 week+8.83%
Current month+6.85%
1 month+36.59%
3 months+58.40%
6 months+30.82%
Current year+41.13%
1 week 20.46
Extreme 20.46
23.15
1 month 17.13
Extreme 17.1327
23.15
Current year 12
Extreme 12
23.15
1 year 9.96
Extreme 9.9551
23.15
3 years 2.28
Extreme 2.28
23.15
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Fiscal year

Head of Human Resources

120,564 0.0753%
7/2/26 Sell

Founder

-386,240 0.2413%
7/1/26 Sell

Executive/Senior Manager

-487 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+3.71%+8.83%+118.29%+210.99% 3.67B
-0.15%+3.79%+144.14%+97.63% 4.72B
-5.50%-0.75%-29.85%-37.41% 2.04B
-1.51%+39.35%+236.41%+292.59% 2.05B
+7.30%+18.20%+113.68%-37.66% 2.23B
+2.12%+18.88%+188.45%-42.17% 1.07B
-2.39%-1.55%-12.29%+35.95% 875M
-4.16%+6.17%-33.94%-12.03% 513M
-3.06%-3.18%-2.02% - 476M
-8.02%-9.23% - - 179M
Average -1.17%+8.20%+80.32%+63.49% 1.78B
Weighted average by Cap. +0.56%+10.56%+111.37%+96.44%

Financials

2026 *2027 *
Net sales 287M 250M 231M 213M 402M 27.6B 410M 2.76B 1.09B 13.52B 1.08B 1.05B 46.53B 352M 308M 284M 262M 493M 33.92B 504M 3.39B 1.34B 16.61B 1.32B 1.29B 57.19B
Net income -72.6M -63.45M -58.55M -53.96M -102M -6.99B -104M -700M -275M -3.42B -273M -267M -11.79B -38.13M -33.32M -30.75M -28.34M -53.42M -3.67B -54.61M -368M -145M -1.8B -143M -140M -6.19B
Net Debt -135M -118M -109M -100M -189M -12.96B -193M -1.3B -510M -6.35B -506M -494M -21.86B -173M -151M -139M -128M -242M -16.62B -247M -1.66B -654M -8.14B -648M -634M -28.02B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-17 US$22.92 +3.71% 3,233,067
26-07-16 US$22.10 -3.49% 2,447,739
26-07-15 US$22.90 +6.86% 3,986,034
26-07-14 US$21.43 +1.95% 1,889,331
26-07-13 US$21.02 -0.19% 1,844,673
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.92USD
Average target price
22.00USD
Spread / Average Target
-4.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock